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SUMMARY
A 33-year-old woman with multiple sclerosis,
medicated with high doses of methylprednisolone,
cyclophosphamide and glatiramer acetate, was referred
to our department due to acute liver injury. The
laboratory investigation was normal except for weakly
positive antinuclear antibodies. Cyclophosphamide and
glatiramer acetate were suspended, and intravenous
immunoglobulin with maintenance of high doses of
methylprednisolone was initiated. The patient
developed another episode of acute hepatitis so the
immunoglobulin was stopped. After that, she had three
more episodes of elevation of liver enzymes with no
hepatic insufﬁciency while medicated only with high
doses of methylprednisolone. At this time, liver biopsy
showed focal centrilobubar hepatocyte necrosis with
minimal interface hepatitis. After the high doses of
methylprednisolone were suspended, the patient
remained asymptomatic, with normal hepatic enzymes.
This case emphasises that, although rare, induced liver
injury after high doses of methylprednisolone can occur.
BACKGROUND
Drug-induced liver injury (DILI) is an important
cause of acute liver failure with an estimated inci-
dence of 1–10 000 to 1–100 000 treated patients.1 2
The clinical manifestation may vary from transitory
mild elevation of liver enzymes to fulminant liver
failure and death.3 Multiple sclerosis (MS) is a
chronic recurrent autoimmune disease of the
central nervous system, of unknown aetiology.
High doses of intravenous methylprednisolone are
useful for its treatment and are also used in the
treatment of other autoimmune disorders and even
in acute hepatitis.4 Although severe liver injury is
not mentioned among the possible side effects of
methylprednisolone, acute and serious liver injury
induced by corticosteroids can occur. It is
extremely rare with only a few cases described in
the literature.5
CASE PRESENTATION
A 33-year-old woman with a diagnosis of severe
MS 9 months prior, was referred to our hospital
with jaundice that evolved over 4 days, with no
other associated signs or symptoms. In the last sixth
months, she had been treated for her MS with
cyclophosphamide and glatiramer acetate. She had
also been treated with high doses of methyl-
prednisolone 1 g/day, with oral maintenance
because of the severity of the disease. No ethanol
consumption, no toxic exposition and no other
medications were reported. Laboratory analysis
showed total bilirubin of 16 mg/dL (normal
0.3–1.2 mg/dL), direct bilirubin 9.7 mg/dL (normal
0.1–0.5 mg/dL), aspartate aminotransferase (AST)
710 U/L (normal <35 U/L), alanine aminotransfer-
ase (ALT) 2308 U/L (normal <45 U/L), γ-glutamyl
transferase (GGT) 247 U/L (normal <55 U/L),
phosphatase alkaline 92 U/L (normal 40–150 U/L),
prothrombin index 36%, factor V 76% and factor
VII 17%. Virology for hepatitis B, C and A, herpes
simplex virus, Epstein-Barr virus and cytomegalo-
virus were negative. Serum immunoglobulins were
normal and all autoimmunity markers were nega-
tive, except for antinuclear antibodies, which were
weakly positive (titre of 1:40), with a ﬁne dense
granular pattern. Serum ceruloplasmin, ferritin,
transferrin saturation and α 1 antitrypsin were nega-
tive. The lymphocyte transformation test was nega-
tive for cyclophosphamide and glatiramer acetate.
Abdominal ultrasound with liver and spleen evalu-
ation was normal. During hospitalisation, all the
patient’s medications were suspended and she
received supportive therapy only. She gradually
recovered with analytical improvement on liver
enzymes: total bilirubin 2.6 mg/dL, AST 117 U/L,
ALT 275 U/L, GGT 115 U/L and phosphatase alka-
line 51 U/L. She was discharged with suspension of
cyclophosphamide and glatiramer, but she was
maintained on high doses of methylprednisolone
and started on human normal intravenous immuno-
globulin G (IVIG). After 9 months, she once again
developed acute hepatitis with hepatic insufﬁciency.
The analytical and imagiological studies were nega-
tive and the antinuclear antibodies remained posi-
tive with the same titre. A liver biopsy was
performed, which showed severe interface hepatitis,
and centrilobular hepatocyte necrosis and mild
ﬁbrosis, suggesting an autoimmune or drug-induced
liver injury aetiology. At this time, the patient sus-
pended all medication (including IVIG) except the
high doses of methylprednisolone, and over the fol-
lowing year she developed three more episodes of
elevation of liver enzymes (ALT and AST over ﬁve
times the upper normal limit), but with no hepatic
insufﬁciency. When she was receiving only high
doses of methylprednisolone, the liver biopsy was
repeated, showing a focal centrilobubar hepatocyte
necrosis with minimal interface hepatitis and no
ﬁbrosis. After a multidisciplinary discussion, it was
decided to suspend the high doses of methylpredni-
solone and initiate natalizumab.
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OUTCOME AND FOLLOW-UP
After stopping the high doses of methylprednisolone and start-
ing natalizumab, and after 1 year of follow-up, the patient
remains asymptomatic with normal liver enzymes.
DISCUSSION
We present a case of severe liver injury induced by high doses of
methylprednisolone in a patient with MS. The diagnosis was
established by excluding other causes and other medications,
and by the relationship between drug administration/hepatic
injury and normalisation of liver enzymes after the suspension
of methylprednisolone. In the initial episodes, we could not
exclude the fact that the other medications might also have con-
tributed to liver damage, however, we were able to assume the
normalisation of liver tests after methylprednisolone withdrawal
as a positive dechallenge. Liver dysfunction can occur in patients
with MS, but most times it is related to drug toxicity. On review
of the literature, few cases of liver injury induced by corticoster-
oids were found.5 6 Besides being a rare condition, it has also
been under-reported. The clinical presentation varies from
subtle elevation of liver enzymes to fulminant hepatitis. Also,
the characteristic features on histological examination exhibit a
variety of patterns such as steatohepatitis, interface hepatitis and
bridging necrosis.5 7
DILI is uncommon but it represents the most frequent cause
for drug withdrawal after initial approval and is an important
reason for liver transplant.8 The mechanism of toxicity is pre-
dominantly idiosyncratic, meaning liver injury is unexpected,
and it depends on individual susceptibility related to risk factors
and genetic polymorphisms. Idiosyncratic lesions can be divided
into immunoallergic and metabolic (non-allergic). The immu-
noallergic reaction occurs due to the interaction of the drug or
its metabolites with cells of the immune system, leading to
necrosis and apoptosis of hepatocytes. It can be associated with
symptoms of hypersensitivity (eg, rash, fever, joint pain). The
metabolic reaction occurs because of an aberrant metabolism of
the drug leading to local accumulation of toxic metabolites, sub-
sequent oxidative stress and cell necrosis.9 10 The exact mechan-
ism responsible for hepatic injury related to methylprednisolone
is unknown. Some authors relate the injury with reactivation of
HBV infection and others relate it to drug-induced injury linked
to the medication excipient.5 It is also supposed to be related to
the decrease of nuclear factor-κB activity, where activation leads
to tumor necrosis factor-α production that has a protective
effect on the liver.11 In cases of chronic use of low doses of
methylprednisolone, steatosis and steatohepatitis can occur
leading to subtle changes in liver enzymes. In patients with auto-
immune diseases, such as MS, concomitant autoimmune hepa-
titis (AIH) should always be considered since the prevalence of
AIH is 0.017% in the general population and it can be 10 times
higher in patients with MS.12 Distinguishing immune-mediated
DILI from AIH is difﬁcult since the clinical presentation can be
similar and the histological pattern such as centrilobular necrosis
is not helpful in distinguishing the two entities.13 AIH a chronic,
immunologically mediated inﬂammation of the liver. The aeti-
ology is uncertain but the disease can be triggered in genetically
predisposed persons by environmental factors such as viruses,
drugs and herbs. In a report on patients with classical features of
AIH, about 9% were drug induced and most of the cases (90%)
were associated with minocycline and nitrofurantoin.14
In our case, applying the simpliﬁed diagnostic criteria for
AIH was neither compatible nor probable for the disease. The
histological pattern with focal centrilobular necrosis and liver
enzyme normalisation after the discontinuation of the methyl-
prednisolone was in favour of an immune-induced drug liver
injury. Nevertheless, this histological pattern can also be found
in the initial forms of AIH and so, although less probable, we
could not exclude drug-induced AIH.
In conclusion, DILI caused by high doses of methylpredniso-
lone is rare and the mechanism in not exactly known. In
patients with other autoimmune diseases, such as MS, the diag-
nosis is difﬁcult to establish because immune mediated liver tox-
icity and AIH have the same immunological background, and
therefore show the same clinical and histopathological features.
Learning points
▸ Induced liver injury after high doses of methylprednisolone is
rare.
▸ The mechanism of injury is unknown but it seems to be
immune mediated.
▸ Drug-induced liver injury and autoimmune hepatitis may be
difﬁcult to differentiate, because of the similar clinical and
histopathological features.
▸ Patients with multiple sclerosis taking high doses of
methylprednisolone should be monitored.
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